Akebia SVP reports automatic stock sales

Akebia Therapeutics SVP and Chief Accounting Officer Richard C. Malabre reported two stock sales of Akebia Therapeutics, Inc. common shares.

Rhea-AI Filing Summary

Akebia Therapeutics SVP and Chief Accounting Officer Richard C. Malabre reported two stock sales of Akebia Therapeutics, Inc. common shares. On February 2, 2026, he sold 36,142 shares at $1.39 per share and 13,382 shares at $1.39 per share.

The transactions were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025, and were made automatically by the company to cover tax withholding obligations related to vesting of restricted stock units granted on January 31, 2024 and January 31, 2025. After these transactions, Malabre directly owned 299,390 common shares of Akebia.

Insider Trade Summary

Net Seller: 49,524 shares

Net Sell 2 txns

Insider Malabre Richard C

Role SVP, Chief Accounting Officer

Sold 49,524 shs ($69K)

Type	Security	Shares	Price	Value
Sale	Common Stock	36,142	$1.39	$50K
Sale	Common Stock	13,382	$1.39	$19K

Holdings After Transaction: Common Stock — 299,390 shares (Direct)

Footnotes (3)

1. F1. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.
2. F2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
3. F3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Akebia Therapeutics (AKBA) report for Richard C. Malabre?

Akebia’s SVP and Chief Accounting Officer Richard C. Malabre reported two common stock sales on February 2, 2026. He sold 36,142 shares at $1.39 and 13,382 shares at $1.39, as disclosed in the Form 4 insider trading report.

Were Richard C. Malabre’s AKBA stock sales part of a Rule 10b5-1 plan?

Yes. One of Richard C. Malabre’s reported sales was made under a Rule 10b5-1 trading plan adopted on September 8, 2025. Such plans pre-schedule trades, helping executives diversify holdings while reducing the appearance of trading on nonpublic information.

Why did Akebia Therapeutics sell shares to cover taxes for Richard C. Malabre?

Shares were sold automatically by Akebia to cover tax withholding obligations tied to Malabre’s restricted stock units. The transactions related to vesting and settlement of one-third of RSU grants made on January 31, 2024 and January 31, 2025, according to the footnotes.

How many Akebia Therapeutics (AKBA) shares does Richard C. Malabre own after the reported sales?

After the February 2, 2026 transactions, Richard C. Malabre directly owned 299,390 shares of Akebia common stock. The Form 4 shows this post-transaction balance following two sales executed at a price of $1.39 per share.

What prices were received in Richard C. Malabre’s February 2026 AKBA stock sales?

Both reported transactions were executed at $1.39 per share. One sale covered 36,142 shares and the other 13,382 shares, as disclosed in the Form 4 filing detailing Malabre’s February 2, 2026 insider stock activity.

What roles does Richard C. Malabre hold at Akebia Therapeutics (AKBA)?

Richard C. Malabre is an officer of Akebia Therapeutics, serving as Senior Vice President and Chief Accounting Officer. His insider status requires public reporting of company stock transactions on Form 4, including the February 2, 2026 sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malabre Richard C

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST ST.

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S		36,142(1)(2)	D	$1.39	312,772	D
Common Stock	02/02/2026		S		13,382(1)(3)	D	$1.39	299,390	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

2. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.

3. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.

Remarks:

	/s/ Carolyn M. Rucci, attorney-in-fact for Richard C. Malabre	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.